Grekas D, Kalevrosoglou I, Karamouzis M, Geropoulou E, Kabouris H, Tourkantonis A
First Medical Department, University Hospital AHEPA, Thessaloniki, Greece.
Clin Nephrol. 2001 Feb;55(2):115-20.
The reasons for poor control of blood pressure in hemodialysis (HD) patients are not clear, while patients have achieved their desirable dry weight and excess weight are not different between the hypertensive and normotensive patients. A link between sympathetic activity and HD hypertension could be an alternative explanation.
We studied the effect of sympathetic and plasma renin-aldosterone activity of 10 hypertensive patients, 5 men and 5 women, aged from 30 to 60 years. The results were compared to those of another 10 normotensive hemodialysis patients. Blood samples were taken before HD and at the end of a 4-hour HD session for plasma aldosterone (ALDO), renin activity (PRA), adrenaline and noradrenaline determination. One month dialysis records, which includes 13 dialysis sessions and 26 blood pressure readings for each patient were used, for pre-dialysis and post dialysis mean arterial blood pressure (MAP) measurement.
Pre-dialysis plasma adrenaline was 124.12 +/- 12.93 pg/ml vs. 121.12 +/- 14.71 pg/ml and plasma noradrenaline was 260.88 +/- 140.86 pg/ml vs. 138.11 +/- 122 +/- 32 pg/ml for hypertensive and normotensive patients, respectively. Post-dialysis plasma adrenaline and noradrenaline levels were 119.37 +/- 8.81 pg/ml vs. 120.62 +/- 15.35 pg/ml and 210.44 +/- 126.71 pg/ml vs. 94.88 +/- 64.05 pg/ml for hypertensive and normotensive patients, respectively. Pre-dialysis PRA was 8.70 +/- 6.37 ng/ml/h vs. 2.77 +/- 1.8 ng/ml/h and plasma ALDO was 457.07 +/- 245.54 pg/ml vs. 197.74 +/- 87.46 pg/ml for hypertensive and normotensive patients, respectively. Pre-MAP was 109.76 +/- 5.21 mmHg vs. 99.28 +/- 7.13 mmHg and post-MAP was 107.22 +/- 6.74 mmHg, vs. 91.61 +/- 7.27 mmHg for hypertensive and normotensive patients, respectively. Plasma ALDO and fluid volume removed by ultrafiltration were found to be significantly correlated (p < 0.05). PRA and plasma adrenaline-noradrenaline levels were not correlated with MAP or body weight alterations.
It is suggested that sympathetic activity, as it was expressed by plasma catecholamine alterations, is not associated with hemodialysis hypertension.
血液透析(HD)患者血压控制不佳的原因尚不清楚,尽管患者已达到理想干体重,且高血压患者与血压正常患者之间的超重情况并无差异。交感神经活动与HD高血压之间的联系可能是另一种解释。
我们研究了10例年龄在30至60岁之间的高血压患者(5名男性和5名女性)的交感神经及血浆肾素 - 醛固酮活性的影响。将结果与另外10例血压正常的血液透析患者的结果进行比较。在HD前及4小时HD疗程结束时采集血样,用于测定血浆醛固酮(ALDO)、肾素活性(PRA)、肾上腺素和去甲肾上腺素。使用一个月的透析记录,其中包括每位患者13次透析疗程和26次血压读数,用于测量透析前和透析后的平均动脉血压(MAP)。
高血压患者透析前血浆肾上腺素为124.12±12.93 pg/ml,血压正常患者为121.12±14.71 pg/ml;高血压患者透析前血浆去甲肾上腺素为260.88±140.86 pg/ml,血压正常患者为138.11±122±32 pg/ml。高血压患者透析后血浆肾上腺素和去甲肾上腺素水平分别为119.37±8.81 pg/ml和120.62±15.35 pg/ml,血压正常患者分别为210.44±126.71 pg/ml和94.88±64.05 pg/ml。高血压患者透析前PRA为8.70±6.37 ng/ml/h,血压正常患者为2.77±1.8 ng/ml/h;高血压患者血浆ALDO为457.07±245.54 pg/ml,血压正常患者为197.74±87.46 pg/ml。高血压患者透析前MAP为109.76±5.21 mmHg,血压正常患者为99.28±7.13 mmHg;高血压患者透析后MAP为107.22±6.74 mmHg,血压正常患者为91.61±7.27 mmHg。发现血浆ALDO与超滤去除的液体量显著相关(p<0.05)。PRA以及血浆肾上腺素 - 去甲肾上腺素水平与MAP或体重变化无关。
提示血浆儿茶酚胺变化所表现出的交感神经活动与血液透析高血压无关。